Online citations, reference lists, and bibliographies.
← Back to Search

Botulinum Toxin Type A (BOTOX) For Treatment Of Migraine.

W. Binder, M. Brin, A. Blitzer, J. Pogoda
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
An open-label study and 2 double-blind, placebo-controlled studies have provided supporting evidence of botulinum toxin type A (BTX-A) as an effective, well-tolerated treatment for migraine. Observed durations of benefit were consistent with known properties of BTX-A. Findings suggest that response may vary by features of preinjection headaches, such as migraine frequency. The precise mechanism by which BTX-A provides pain relief is hypothesized to be related not only to acetylcholine inhibition but also to a blocking action on the parasympathetic nervous system. Additional studies that control factors likely to be related to response may lead to better understanding of the BTX-A effect on migraine and an optimal treatment protocol.
This paper references
10.1046/j.1526-4610.2000.00066.x
Botulinum Toxin Type A as a Migraine Preventive Treatment
S. Silberstein (2000)
10.1212/WNL.45.3.506
Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm
T. Mezaki (1995)
10.1016/0928-4257(94)90086-8
Inhibition of neurotransmitter release by clostridial neurotoxins correlates with specific proteolysis of synaptosomal proteins
J. Blasi (1994)
10.1111/j.1468-1331.1997.tb00300.x
Cytokines and soluble IL‐4 in patients with acute optic neuritis and multiple sclerosis
F. Sellebjerg (1997)
10.1046/j.1468-1331.2003.00637.x
Parkinson's Disease and Movement Disorders
J. Jankovic (1988)
10.1177/019459989511200410
Rhinorrhea is Decreased in Dogs after Nasal Application of Botulinum Toxin
C. M. Shaari (1995)
10.1212/WNL.45.9.1743
Response and immunoresistance to botulinum toxin injections
J. Jankovic (1995)
10.1111/j.1471-4159.1988.tb02482.x
Characterization of the Inhibitory Action of Botulinum Neurotoxin Type A on the Release of Several Transmitters from Rat Cerebrocortical Synaptosomes
A. C. Ashton (1988)
10.1067/mhn.2000.110960
Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study
W. Binder (2000)
10.1113/jphysiol.1936.sp003434
The technique of suprarenalectomy in the guinea‐pig and the survival period and cause of death of guinea‐pigs after bilateral suprarenalectomy
H. Simmons (1936)
10.1016/0306-4522(87)90094-7
Selective location of acceptors for botulinum neurotoxin a in the central and peripheral nervous systems
J. Black (1987)
Treatment of tension type headache by local injection of botulinum toxin
Maja Relja (1997)
10.1016/0002-9394(88)90016-5
Negative antibody response to long-term treatment of facial spasm with botulinum toxin.
R. Gonnering (1988)
10.1002/ANA.410280213
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
P. J. Goadsby (1990)
Migraine. Patterns of healthcare use.
P. Stang (1994)
10.1002/MDS.870080411
Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A
P. E. Greene (1993)
10.1016/0014-2999(89)90229-X
Effects of botulinum A toxin on presynaptic modulation of evoked transmitter release.
R. Nakov (1989)
10.1016/0304-3959(91)90066-7
Clinical and pathophysiological observations in migraine and tension-type headache explained by integration of vascular, supraspinal and myofascial inputs
J. Olesen (1991)
10.1016/0006-8993(85)90535-9
Extracranial vasodilatation mediated by vasoactive intestinal polypeptide (VIP)
P. Goadsby (1985)
10.1046/j.1526-4610.2000.00044.x
Treatment of Tension‐type Headache With Botulinum Toxin Type A: A Double‐Blind, Placebo‐Controlled Study
J. Rollnik (2000)
10.1016/0304-3959(94)90048-5
Botulinum toxin in the treatment of myofascial pain syndrome
W. Cheshire (1994)
10.1046/j.1526-4610.1996.3606352.x
The Placebo Effect in Acute Headache Management: Ketorolac, Meperidine, and Saline in the Emergency Department
R. Harden (1996)
10.1097/00019052-199406000-00016
Pathophysiology of migraine and tension-type headache.
A. Zagami (1994)
10.1016/0306-4522(90)90001-7
Neuropeptide Y Co-Exists with Vasoactive Intestinal Polypeptide and Acetylcholine in Parasympathetic Cerebrovascular Nerves Originating in the Sphenopalatine, OTIC, and Internal Carotid Ganglia of the Rat
N. Suzuki (1990)
10.1046/j.1526-4610.1998.3806468.x
Botulinum Toxin A, Adjunctive Therapy for Refractory Headaches Associated With Pericranial Muscle Tension
A. Wheeler (1998)
10.1111/J.1432-1033.1987.TB11494.X
Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes.
J. Sánchez-Prieto (1987)
Overview of treatment diagnosis and of migraine
S. Silberstein (1994)
10.1001/ARCHOTO.123.4.389
The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients.
A. Blitzer (1997)
10.1002/MDS.870020402
Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm
M. Brin (1987)
10.1056/NEJM199201303260516
Therapeutic use of type F botulinum toxin.
C. Ludlow (1992)
10.1002/ANA.410160202
The neurobiology of vascular head pain
M. Moskowitz (1984)
10.1002/(SICI)1097-4598(1997)6+<146::AID-MUS10>3.0.CO;2-4
Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology
M. Brin (1997)
10.1002/MUS.880180214
Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp
R. Kaji (1995)
10.1016/s0021-9258(19)36614-1
Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action.
H. McMahon (1992)
10.1097/00000542-199403000-00041
Treatment of myofascial pain with botulinum A toxin.
M. Acquadro (1994)
10.1046/j.1526-4610.1997.3704253.x
Botulinum Toxin Injection for Cervicogenic Headache
D. Hobson (1997)
Overview of diagnosis and treatment of migraine
S. Silberstein (1994)
Migraine prevalence. A review of population-based studies.
W. Stewart (1994)
10.1002/MDS.870130128
Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections
C. Sankhla (1998)
The economic cost of migraine. Present state of knowledge.
G. de Lissovoy (1994)
10.1111/j.1526-4610.1994.hed3408458.x
Tension Headache: Botulinum Toxin Paralysis of Temporal Muscles
J. A. Zwart (1994)
10.3109/00016489309135834
Botulinum A toxin effects on rat jaw muscle spindles.
G. Filippi (1993)
10.1016/0014-5793(90)80582-4
Ca2+‐dependent noradrenaline release from permeabilised PC 12 cells is blocked by botulinum neurotoxin A or its light chain
C. McInnes (1990)
10.1136/jnnp.59.6.601
Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.
G. Sheean (1995)
10.1016/0223-5234(87)90042-0
Cellular and molecular basis of cholinergic function
M. Dowdall (1987)
10.1523/JNEUROSCI.15-01-00520.1995
Calcitonin gene-related peptide: possible role in formation and maintenance of neuromuscular junctions
C. Sala (1995)
RECENT ADVANCES IN MIGRAINE MANAGEMENT
Cady Rk (1993)
10.1046/j.1526-4610.1998.3805366.x
Headache and Facial Pain Responsive to Botulinum Toxin: An Unusual Presentation of Blepharospasm
S. Johnstone (1998)
10.1002/(SICI)1097-4598(1997)6+<129::AID-MUS9>3.0.CO;2-B
Botulinum toxin: Historical perspective and potential new indications
J. Jankovic (1997)



This paper is referenced by
10.1016/j.toxicon.2009.02.034
Immune recognition of BoNTs A and B: how anti-toxin antibodies that bind to the heavy chain obstruct toxin action.
M. Atassi (2009)
10.3390/toxins11110641
Using Botulinum Toxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome—Possible Pathomechanisms and Practical Issues
J. Jhang (2019)
10.1186/s10194-017-0781-7
OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study
D. Ranoux (2017)
10.3346/jkms.2010.25.4.517
Anatomical Consideration of the Anterior and Lateral Cutaneous Nerves in the Scalp
S. M. Jeong (2010)
10.1016/S1047-9651(03)00063-9
Botulinum toxins in pain management.
M. Royal (2003)
10.1016/S0304-3959(01)00292-5
Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes
H. Göbel (2001)
Leczenie migreny przewlekłej — zalecenia opracowane przez Grupę Ekspertów Polskiego Towarzystwa Bólów Głowy i Sekcji Badania Bólu Polskiego Towarzystwa Neurologicznego na podstawie międzynarodowych zaleceń i najnowszej literatury
Jacek J. Rożniecki (2018)
10.1016/S1047-9651(03)00094-9
Botulinum toxins in the treatment of migraine and tension-type headaches.
P. Winner (2003)
10.1111/j.1526-4610.2004.04147.x
Botulinum Neurotoxin Type A in the Preventive Treatment of Refractory Headache: A Review of 100 Consecutive Cases
S. Tepper (2004)
10.1016/j.jmig.2008.11.006
The use of botulinum toxin in the pelvic floor for women with chronic pelvic pain-a new answer to old problems?
J. Abbott (2009)
10.5530/jyp.2016.1.2
Botulinum toxin - An Innovative Treatment Approach In Dental Practice
Pushpalatha Govindaraju (2016)
Novel Potential Antimigraine Compounds: Carotid and Systemic Haemodynamic Effects in a Porcine Model of Migraine
K. Kapoor (2003)
10.1007/s00415-004-1103-y
Botulinum toxin in migraine prophylaxis
H. Göbel (2004)
10.1001/jama.2012.505
Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis.
J. Jackson (2012)
Efficacy of Botulinum Toxin-A Treatment in Chronic Migraine – Kuwait Experience
J.Y. Al-Hashel (2015)
10.1007/978-3-540-74380-4_80
Botox: Its Use in Facial Lines and Wrinkles
J. S. Schwartz (2009)
10.1590/0004-282X20150109
OnabotulinumtoxinA for trigeminal neuralgia: a review of the available data.
P. Kowacs (2015)
10.1016/j.molimm.2008.06.031
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment.
M. Atassi (2008)
10.2147/NDT.S17923
Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine
Carrie E. Robertson (2012)
10.1016/j.pediatrneurol.2010.06.001
Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache.
K. Ahmed (2010)
10.1097/01.moo.0000122308.13359.e6
Botulinum toxin and the management of chronic headaches
S. Evers (2004)
10.1016/j.toxicon.2009.01.036
Gynecological indications for the use of botulinum toxin in women with chronic pelvic pain.
J. Abbott (2009)
10.1179/2151090314Y.0000000022
Botulinum toxin for the treatment of bruxism
Neslihan Tinastepe (2014)
10.1002/hed.10340
Botulinum toxin type A for the treatment of chronic neck pain after neck dissection
Claus Wittekindt Vasan (2004)
10.1016/S0889-857X(02)00004-2
Management of peripheral pain generators in fibromyalgia.
J. Borg-Stein (2002)
10.1186/s40902-016-0051-7
A clinical evaluation of botulinum toxin-A injections in the temporomandibular disorder treatment
H. Kim (2016)
10.1097/RHU.0b013e3181953b14
Repeat Injections of Intra-Articular Botulinum Toxin A for the Treatment of Chronic Arthritis Joint Pain
J. Singh (2009)
2003 Faculty Bibliography of Publications
M. Lindsey (2000)
10.1007/s10072-016-2665-z
Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine
B. E. Demiryurek (2016)
Botulinum Toxin Type A for Chronic Pain and Pelvic Floor Spasm in Women
J. Abbott (2006)
10.17116/jnevro20171178144-48
[Efficacy of different doses of botox in treatment of chronic migraine].
M. Naprienko (2017)
10.1136/bmj.325.7374.1188
The changed image of botulinum toxin
V. Misra (2002)
See more
Semantic Scholar Logo Some data provided by SemanticScholar